Table 2 miR-10b-5p: copies per microliter of serum according to clinicopathological features
Feature | Cohort A (Italy) | Cohort B (USA) | |
|---|---|---|---|
Average copies/μL ± SD | Average copies/μL ± SD | ||
(n = number of patients) | (n = number of patients) | ||
Tumor size (pT) | pT1 | 108.7 ± 78.0 (n = 19) | 98.6 ± 47.3 (n = 28) |
pT2 | 97.3 ± 55.9 (n = 6) | 143.4 ± 70.3 (n = 27) | |
pT3 | / | 75.0 ± 11.9 (n = 4) | |
Lymph node involvement (pN) | pN0 | 88.7 ± 37.2 (n = 18) | 101.2 ± 54.6 (n = 35) |
pN1-2-3 | 113.3 ± 89.4 (n = 7) | 145.2 ± 70.8 (n = 23) | |
Stage | I | 82.9 ± 28.5 (n = 14) | 91.3 ± 45.9 (n = 23) |
II | 107.7 ± 79.9 (n = 10) | 128.0 ± 61.8 (n = 25) | |
III | 134.0 (n = 1) | 130.5 ± 60.2 (n = 8) | |
IV | / | 242.2 ± 110.3 (n = 2) | |
Grade | I | 80.8 ± 36.5 (n = 5) | 114.9 ± 43.2 (n = 11) |
II | 112.7 ± 88.6 (n = 18) | 91.2 ± 58.8 (n = 13) | |
III | 105.0 ± 54.3 (n = 5) | 136.0 ± 74.81 (n = 34) | |
ER/PR status | ER+/PR+ | 142.1 ± 98.44 (n = 17) | 115.0 ± 60.1 (n = 35) |
ER-/PR- | 74.0 (n = 1) | 131.9 ± 89.4 (n = 16) | |
HER2/neu receptor | Positive | 103.7 ± 80.8 (n = 3) | 112.9 ± 65.5 (n = 11) |
Negative | 115.8 ± 88.4 (n = 25) | 145.8 ± 75.0 (n = 44) | |
Triple Negatives | ER-/PR-/HER2- | 74.0 (n = 1) | 117.8 ± 90.2 (n = 9) |
Others | 118.2 ± 85.61 (n = 27) | 121.5 ± 63.36 (n = 49) | |